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Purpose: The overactive bladder (OAB) syndrome is characterized by urgency usually with frequency and nocturia. Tamsulosin, 
α1-adrenergic receptor antagonist, is widely used to reduce symptoms of urinary obstruction and prostatic hyperplasia. Tamsu-
losin can across the blood-brain barrier. We investigated the effects of tamsulosin on the symptoms of OAB in relation to neuro-
nal activity using rats. 
Methods: Adult female Sprague-Dawley rats, weighing 250±10 g (9 weeks old), were used in this study. The animals were divid-
ed into five groups (n=8 in each group): control group, OAB-induced group, OAB-induced and 0.01 mg/kg tamsulosin-treated 
group, OAB-induced and 0.1 mg/kg tamsulosin-treated group, and OAB-induced and 1 mg/kg tamsulosin-treated group. OAB 
was induced by intraperitoneal injection of cyclophosphamide (75 mg/kg) every third day for 10 days. The rats in the tamsulo-
sin-treated groups orally received tamsulosin once a day for 14 consecutive days at the respective dose of the groups, starting 1 
day after the induction of OAB. Cystometry for bladder pressure determination, immunohistochemistry for c-Fos, nicotinamide 
adenine dinucleotide phosphate-diaphorase histochemistry for nitric oxide synthase (NOS) in the neuronal voiding centers and 
western blot for inducible NOS in the bladder were conducted. 
Results: Cyclophosphamide injection enhanced contraction pressure and time, representing the induction of OAB. Contraction 
pressure and time were significantly suppressed by tamsulosin treatment. c-Fos and NOS expressions in the neuronal voiding 
centers were enhanced by induction of OAB. OAB-induced c-Fos and NOS expressions were suppressed by tamsulosin treat-
ment.
Conclusions: Tamsulosin exerts inhibitory effect on neuronal activation in the neuronal voiding centers of OAB. The present 
results suggest the possibility that tamsulosin is effective therapeutic modality for ameliorating the symptoms of OAB. 
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INTRODUCTION
The overactive bladder (OAB) syndrome is characterized by 
urgency usually with frequency and nocturia [1]. OAB repre-
sents a substantial problem in clinical practice, with an overall 
prevalence of 16 to 17% of adults worldwide. OAB is a symptom 
complex affecting both women and men, and it is more com-
mon in elder, however young person also have OAB symptoms 
as well [2]. The cost of managing OAB in the United States has 
been estimated to be as high as 6 billion United States Dollars 
[3]. In addition, patients with OAB tend to restrict their activi-
ties and many patients experience sleep disruption, depression, 
and poor life quality [2]. 
  Normally, the detrusor muscle contracts and relaxes in re-
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sponse to the volume of urine in the bladder and the initiation 
of urination. In OAB patients, however, bladder smooth muscle 
contracts spastically, sometimes as unknown cause, induces sus-
tained high bladder pressure, and causes urgent urination [3]. 
Cystometry measures the pressure and capacity of the bladder, 
and thereby can be used to evaluate the function of detrusor 
muscle and bladder in OAB patients [4]. 
  Micturition involves processes within urinary tract and brain. 
Neuroanatomical tracing studies revealed that bladder and ex-
ternal urethral sphincter are innervated both directly and indi-
rectly by many central nervous system regions, including the 
pontine micturition center (PMC), locus coeruleus, hypothala-
mus, preoptic area, and spinal cord [5]. Using a positron emis-
sion tomography scanner, Blok and Holstege [6] demonstrated 
that blood flow to the dorsomedial pons, periaqueductal gray 
(PAG), hypothalamus, and cerebral cortex was increased dur-
ing micturition. Moreover, bladder hyperactivity was shown to 
induce chemical changes in the spinal cord [7]. 
  The transcription factor c-Fos is encoded by the immediately 
early gene c-Fos, and c-Fos expression has been used as a mark-
er of neuronal activity [8]. Stimulation of the bladder increased 
c-Fos-immunoreactive neurons in the PAG, PMC, and spinal 
cord [9,10]. 
  Nitric oxide (NO) plays important physiologic roles in vari-
ous organs such as regulation of vascular smooth muscle tone 
and neurotransmission of the peripheral nervous system and 
central nervous system [11]. Research on pathological bladder 
activity has shown the involvement of the NO pathway [12]. NO 
is synthesized from L-arginine by nitric oxide synthase (NOS). 
There are multiple forms of NOS, which are classified accord-
ing to physical and chemical properties into three groups, neu-
ronal NOS (nNOS), inducible NOS (iNOS), and endothelial 
NOS (eNOS). NOS is demonstrated in the lower urinary tract 
in animals and humans, and inducible NOS (iNOS) expression 
is associated with inflammation in the bladder [11]. Expression 
of iNOS was increased during bladder injury [13], thus NO plays 
an important role in non-adrenergic and non-cholinergic neu-
rotransmission in a variety of organ systems, including lower 
urinary tract and voiding centers [13,14]. 
  The most common drugs for the treatment of OAB are anti-
muscarinic drugs, however, limited efficacy and side effects such 
as dry mouth, somnolence, constipation, and blurred vision have 
been reported [2]. Tamsulosin is in a class of medications clas-
sified in α1-adrenergic receptor antagonists, and this drug is 
widely used to reduce urinary obstruction and to relieve associ-
ated manifestations in hypertensive or normotensive patients 
with symptomatic benign prostatic hyperplasia [15]. In addition, 
the crucial aspect for tamsulosin is its ability to cross the blood-
brain barrier [16]. Several studies showed that antimuscarinic 
drugs treatment with α1-adrenergic receptor antagonists im-
proved lower urinary tract symptoms in humans [17,18]. 
  Currently, treatment with α1-adrenergic receptor antagonists 
is suggested as the standard care for humans with lower urinary 
tract symptoms, because these drugs reduce smooth muscle tone 
in the prostate and bladder neck and also decrease bladder out-
let resistance [18,19]. In many cases, OAB symptoms coexist 
with benign prostate hyperplasia or bladder outlet obstruction 
not caused by prostate origin, as a results pharmacotherapies 
targeting only prostate (and not bladder) may not sufficiently 
alleviate OAB symptoms [19]. The effects of α1-adrenergic re-
ceptor antagonists on voiding and storage symptoms have been 
suggested, however the mechanisms by which α1-adrenergic re-
ceptor antagonists may improve OAB remain controversial. In 
addition, there have been no reports on the efficacy of tamsulo-
sin in producing changes in the neuronal activity of voiding 
centers in relation with OAB symptoms. 
  In the present study, we investigated the effects of tamsulosin 
on urinary bladder function, iNOS expression in the bladder, 
and c-Fos and NOS expressions in the neuronal voiding centers 
(medial preoptic nucleus [MPA], ventrolateral periaqueductal 
gray [vlPAG], PMC, and spinal cord [L4-L5]) following the in-
duction of OAB in rats. For this study, cystometry, immunohis-
tochemistry for c-Fos, histochemistry for nicotinamide adenine 
dinucleotide phosphate-diaphorase (NADPH-d), and western 
blot for iNOS were performed.
MATERIALS AND METHODS
Animals
Adult female Sprague-Dawley rats, weighing 250±10 g (9 weeks 
old), were obtained from a commercial breeder (Orient Co., 
Seoul, Korea) for the experiment. The experimental procedures 
were performed in accordance with the animal care guidelines 
of the National Institute of Health and the Korean Academy of 
Medical Sciences. Each animal was housed under controlled 
temperature (23±2°C) and lighting (8 A.M. to 8 P.M.) condi-
tions with food and water made available ad libitum before and 
after surgery. 
  The animals were randomly divided into five groups (n=8 in 
each group): the control group, the OAB-induced group, the www.einj.org    15
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OAB-induced and 0.01 mg/kg tamsulosin-treated group, the 
OAB-induced and 0.1 mg/kg tamsulosin-treated group, and the 
OAB-induced and 1 mg/kg tamsulosin-treated group. 
  The rats in the tamsulosin-treated groups orally received 
tamsulosin (Harnal, Astellas Pharma Inc., Tokyo, Japan) once a 
day for consecutive 14 days at the respective doses of the 
groups, starting 1 day after the induction of OAB. The animals 
in the control group and in the OAB-induced group received 
the same amount of distilled water. 
Induction of Overactive Bladder
OAB model was induced as the previously described method 
[20]. For the induction of chronic OAB model, 75 mg/kg cyclo-
phosphamide (Sigma Chemical Co., St. Louis, MO, USA) was 
intraperiotneally injected every third day for 10 days. The con-
trol rats intraperitoneally received volume-matched saline. 
Cystometry
Bladder function in rats was evaluated by cystometry 14 days 
after the induction of OAB. The rats were anesthetized with Zo-
letil 50 (10 mg/kg, i.p.; Vibac Laboratories, Carros, France). A 
sterile polyethylene catheter (PE50) was inserted into the ure-
thra through the bladder dome. The catheter was connected to 
a pressure transducer (Havard Apparatus, Holliston, MA, USA) 
and syringe pump (Havard Apparatus) via a 3-way stopcock to 
record intravesical pressure and to infuse saline into the blad-
der. After the bladder was emptied, cystometry was performed 
with infusion of 0.5 mL saline. The contraction pressure and 
contraction time in the bladder were monitored using Lab-
scribe (iWork System Inc., Dover, NH, USA).
Tissue Preparation 
After tissue preparation of the bladder, the rats were transcardi-
ally perfused with 50 mM phosphate-buffered saline (PBS), fol-
lowed by 4% paraformaldehyde in 100 mM sodium phosphate 
buffer (PB) at pH 7.4. The brain was removed, postfixed in the 
same fixative overnight, and transferred into a 30% sucrose so-
lution for cryoprotection. Serial coronal sections of 40 μm thick-
ness were made with a freezing microtome (Leica Biosystems 
Nussloch GmbH, Nussloch, Germany). The PMC was selected 
from the region spanning from Bregma -9.68 to -9.80 mm, the 
vlPAG was selected from the region spanning from Bregma -7.64 
to -8.00 mm, the MPA was selected from the region spanning 
from Bregma -0.26 to 0.80 mm, and the spinal cord was select-
ed from the L4-L5 regions. Ten sections on average in each re-
gion were collected from each rat. 
c-Fos Immunohistochemistry
The central micturition areas were stained for c-Fos expression. 
Free-floating tissue sections were incubated overnight with rab-
bit anti-c-Fos antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) at a dilution of 1:1,000, and the sections were 
then incubated for 1 hour with biotinylated anti-rabbit second-
ary antibody (Vector Laboratories Inc., Burlingame, CA, USA). 
The sections were subsequently incubated with avidin-biotin-
peroxidase complex (Vector Laboratories Inc.) for 1 hour at 
room temperature. Immunoreactivity was visualized by incu-
bating the sections in a solution consisting of 0.05% 3,3-diami-
nobenzidine and 0.01% H2O2 in 50 mM Tris-buffer (pH 7.6) 
for approximately 3 minutes. The sections were then washed 
three times with PBS and mounted onto gelatine-coated slides. 
The slides were air-dried overnight at room temperature, and 
coverslips were mounted by using Permount mounting medi-
um (Thermo Fisher Scientific Inc., Waltham, MA, USA).
NADPH-d Histochemistry
The central micturition areas were stained for NOS activity. In 
brief, free-floating sections were incubated at 37°C for 60 min-
utes in 100 mM PBS (pH 7.4) containing 0.3% Triton X-100, 0.1 
mg/mL nitroblue tetrazolium, and 0.1 mg/mL β-NADPH. The 
sections were then washed three times with PBS and mounted 
onto gelatin-coated slides. The slides were air dried overnight at 
room temperature, and coverslips were mounted by using Per-
mount mounting medium (Thermo Fisher Scientific Inc.).
iNOS Western Blot Analysis
The bladder tissues were collected, and then immediately fro-
zen at -80°C. The bladder tissues were homogenized on ice, and 
lysed in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 0.5% deoxycholic acid, 1% Nonidet P40, 0.1% sodi-
um dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), and 100 mg/mL leupeptin. Protein content was mea-
sured by using a Bio-Rad colorimetric protein assay kit (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). Protein in amounts of 
30 μg was separated on SDS-polyacrylamide gels and transferred 
onto a nitrocellulose membrane. Mouse actin antibody (1:500; 
Santa Cruz Biotechnology Inc.) and rabbit iNOS antibody 
(1:1,000; Santa Cruz Biotechnology Inc.) were used as the pri-
mary antibodies. Horseradish peroxidase-conjugated anti-rab-
bit antibody for iNOS (1:2,000; Vector Laboratories Inc.) was 16    www.einj.org
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used as the secondary antibody. Experiments were performed 
under normal laboratory conditions and at room temperature 
except for membrane transfer. Membrane transfer was per-
formed at 4°C with a cold pack and prechilled buffer. Band de-
tection was performed by use of an enhanced chemilumines-
cence detection kit (Santa Cruz Biotechnology Inc.). 
Data Analysis
The number of c-Fos-positive and NADPH-d-positive cells in 
the MPA, PMC, vlPAG, and spinal cord (L4-L5) regions were 
counted hemilaterally through a light microscope (Olympus Co., 
Tokyo, Japan). The area of the MPA, PMC, vlPAG, and spinal 
cord (L4-L5) regions from each slice was measured by using an 
Image-Pro Plus computer-assisted image analysis system (Me-
dia Cybernetics Inc., Silver Spring, MD, USA) attached to a light 
microscope (Olympus Co.). To compare the relative expression 
of iNOS proteins, detected bands were calculated densitometri-
cally by using Molecular Analyst ver. 1.4.1 (Bio-Rad Laborato-
ries Inc.). Statistical analysis was performed by using one-way 
analysis of variance followed by Duncan’s post-hoc test, and the 
results are expressed as the mean±standard error of the mean. 
Significance was set as P<0.05.
RESULTS
Effects of Tamsulosin on the Contraction Pressure and Time
The contraction pressure and contraction time from the cystom-
etry are presented Fig. 1. The contraction pressure was 3.40± 
0.27 cmH2O in the control group, 9.12±0.62 cmH2O in the 
OAB-induced group, 4.13±0.02 cmH2O in the OAB-induced 
and 0.01 mg/kg tamsulosin-treated group, 5.40±0.43 cmH2O 
in the OAB-induced and 0.1 mg/kg tamsulosin-treated group, 
and 6.20±1.61 cmH2O in the OAB-induced and 1 mg/kg tam-
sulosin-treated group. 
  These results showed that contraction pressure was increased 
by the induction of OAB (P<0.05), and that tamsulosin treat-
ment significantly decreased the OAB-induced contraction pres-
sure in a dose-dependent manner (P<0.05). The suppressing 
effect of tamsulosin on contraction pressure appeared most po-
tent with the lowest dose of 0.01 mg/kg (P<0.05). 
  The contraction times was 20.80±0.87 seconds in the con-
trol group, 29.74±0.96 seconds in the OAB-induced group, 
16.92±0.40 seconds in the OAB-induced and 0.01 mg/kg tam-
sulosin-treated group, 16.98±0.02 seconds in the OAB-induced 
and 0.1 mg/kg tamsulosin-treated group, and 18.79±0.56 sec-
onds in the OAB-induced and 1 mg/kg tamsulosin-treated 
group. 
  These results showed that contraction time was increased by 
the induction of OAB (P<0.05) and that tamsulosin treatment 
significantly decreased the OAB-induced contraction time (P< 
0.05), although the improvement was not dose-dependent.
Effects of Tamsulosin on the c-Fos Expressions in the 
Neuronal Voiding Centers 
Photomicrographs of c-Fos-positive cells in the neuronal void-
ing centers are presented in Fig. 2. In the MPA region, the num-
ber of c-Fos-positive cells was 73.12±7.53/section in the con-
trol group, 142.00±8.17/section in the OAB-induced group, 
93.75±18.22/section in the OAB-induced and 0.01 mg/kg tam-
Fig. 1. Effect of tamsulosin on contraction pressure and time in 
the cystometry. Upper: Graph of cystometry in each group. (A) 
Control group, (B) overactive bladder (OAB)-induced group, 
(C) OAB-induced and 0.01 mg/kg tamsulosin-treated group, 
(D) OAB-induced and 0.1 mg/kg tamsulosin-treated group, (E) 
OAB-induced and 1 mg/kg tamsulosin-treated group. Lower: 
Analysis of contraction pressure (left) and contraction time 
(right) in each group. 
a,b) Statistically significant differences (P<
0.05) after Duncan post-hoc test. For example, groups marked 
with different letters differ statistically.
C
o
n
t
r
a
c
t
i
o
n
 
p
r
e
s
s
u
r
e
 
o
f
 
b
l
a
d
d
e
r
 
(
c
m
H
2
O
)
10
8
6
4
2
0
A
a)
B
b)
C
a)
D
a, b)
E
a, b)
C
o
n
t
r
a
c
t
i
o
n
 
t
i
m
e
 
o
f
 
b
l
a
d
d
e
r
 
(
s
e
c
)
40
30
20
10
0
A
a)
B
b)
C
a)
D
a)
E
a)
50
40
30
20
10
0
-10
c
m
H
2
O
  10  20  30  40  50  60
Minutes E
50
40
30
20
10
0
-10
c
m
H
2
O
  10  20  30  40  50  60
Minutes
50
40
30
20
10
0
-10
c
m
H
2
O
  10  20  30  40  50  60
Minutes A B
50
40
30
20
10
0
-10
c
m
H
2
O
  10  20  30  40  50  60
Minutes
50
40
30
20
10
0
-10
c
m
H
2
O
  10  20  30  40  50  60
Minutes C Dwww.einj.org    17
  Kim, et al.  •  Effects of Tamsulosin on Overactive Bladder
http://dx.doi.org/10.5213/inj.2012.16.1.13
INJ
Fig. 2. Effect of tamsulosin on c-Fos expressions in the neuronal voiding centers (medial preoptic nucleus [MPA], ventrolateral peri-
aqueductal gray [vlPAG], pontine micturition center [PMC], spinal cord [L4-L5] regions) after the induction of overactive bladder 
(OAB). Upper: Photomicrographs of c-Fos-positive cells in the neuronal voiding centers. The sections were stained for c-Fos immu-
noreactivity (brown). The scale bar represents 200 μm. Control group (CON), OAB-induced group (OAB), OAB-induced and 0.01 
mg/kg tamsulosin-treated group (OAB-T-0.01). Lower: Number of c-Fos-positive cells in each group. (A) Control group, (B) OAB-
induced group, (C) OAB-induced and 0.01 mg/kg tamsulosin-treated group, (D) OAB-induced and 0.1 mg/kg tamsulosin-treated 
group, (E) OAB-induced and 1 mg/kg tamsulosin-treated group. 
a-d)Statistically significant differences (P<0.05) after Duncan post-
hoc test. For example, groups marked with different letters differ statistically.
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sulosin-treated group, 115.33±11.98/section in the OAB-in-
duced and 0.1 mg/kg tamsulosin-treated group, and 136.75± 
10.79/section in the OAB-induced and 1 mg/kg tamsulosin-
treated group. 
  In the vlPAG region, the number of c-Fos-positive cells was 
26.46±2.59/section in the control group, 61.07±3.60/section in 
the OAB-induced group, 28.42±3.20/section in the OAB-in-
duced and 0.01 mg/kg tamsulosin-treated group, 39.68±2.36/
section in the OAB-induced and 0.1 mg/kg tamsulosin-treated 
group, and 44.26±3.27/section in the OAB-induced and 1 mg/18    www.einj.org
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kg tamsulosin-treated group. 
  In the PMC region, the number of c-Fos-positive cells was 
15.60±1.70/section in the control group, 49.84±5.59/section in 
the OAB-induced group, 26.71±2.15/section in the OAB-in-
duced and 0.01 mg/kg tamsulosin-treated group, 37.23±2.43/
section in the OAB-induced and 0.1 mg/kg tamsulosin-treated 
group, and 36.00±2.12/section in the OAB-induced and 1 mg/
kg tamsulosin-treated group. 
  In the spinal cord L4-L5 regions, the number of c-Fos-positive 
cells was 9.30±1.48/section in the control group, 30.00± 
1.48/section in the OAB-induced group, 16.62±1.81/section in 
the OAB-induced and 0.01 mg/kg tamsulosin-treated group, 
22.84±1.70/section in the OAB-induced and 0.1 mg/kg tamsu-
losin-treated group, and 24.4±1.97/section in the OAB-induced 
and 1 mg/kg tamsulosin-treated group. 
  These results showed that c-Fos expressions in the neuronal 
voiding centers (MPA, vlPAG, PMC, spinal cord [L4-L5]) were 
increased by the induction of OAB (P<0.05) and that tamsulo-
sin treatment significantly decreased the OAB-induced c-Fos 
expressions in the neuronal voiding centers dose-dependently 
(P<0.05). The suppressing effect of tamsulosin on c-Fos expres-
sions appeared most potent at the dose of 0.01 mg/kg (P<0.05). 
Effects of Tamsulosin on the NOS Expressions in the 
Neuronal Voiding Centers 
Photomicrographs of NADPH-d-positive cells in the neuronal 
voiding centers are presented in Fig. 3. In the MPA region, the 
number of NADPH-d-positive cells was 10.99±1.95/section in 
the control group, 76.34±7.95/section in the OAB-indcuced 
group, 40.11±8.55/section in the OAB-induced and 0.01 mg/
kg tamsulosin-treated group, 59.66±6.45/section in the OAB-
induced and 0.1 mg/kg tamsulosin-treated group, and 66.15± 
7.97/section in the OAB-induced and 1 mg/kg tamsulosin-treat-
ed group. 
  In the vlPAG region, the number of NADPH-d-positive cells 
was 17.35±2.01/section in the control group, 88.74±8.12/sec-
tion in the OAB-induced group, 39.66±4.09/section in the OAB-
induced and 0.01 mg/kg tamsulosin-treated group, 52.15±5.11/ 
section in the OAB-induced and 0.1 mg/kg tamsulosin-treated 
group, and 60.02±8.35/section in the OAB-induced and 1 mg/
kg tamsulosin-treated group. 
  In the PMC region, the number of NADPH-d-positive cells 
was 12.11±1.57/section in the control group, 68.91±9.98/sec-
tion in the OAB-induced group, 29.45±3.15/section in the OAB-
induced and 0.01 mg/kg tamsulosin-treated group, 48.71±4.65/ 
section in the OAB-induced and 0.1 mg/kg tamsulosin-treated 
group, and 50.30±4.15/section in the OAB-induced and 1 mg/
kg tamsulosin-treated group. 
  In the spinal cord L4-L5 regions, the number of NADPH-d-
positive cells was 8.96±1.55/section in the control group, 29.14± 
2.77/section in the OAB-induced group, 10.09±1.35/section in 
the OAB-induced and 0.01 mg/kg tamsulosin-treated group, 
23.97±3.75/section in the OAB-induced and 0.1 mg/kg tamsu-
losin-treated group, and 26.04±3.09/section in the OAB-in-
duced and 1 mg/kg tamsulosin-treated group.
  These results showed that NOS expressions in the neuronal 
voiding centers (MPA, vlPAG, PMC, spinal cord [L4-L5]) were 
increased by the induction of OAB (P<0.05) and that tamsulo-
sin treatment significantly decreased the OAB-induced NOS 
expressions in the neuronal voiding centers dose-dependently 
(P<0.05). The suppressing effect of tamsulosin on NOS expres-
sions appeared most potent at the dose of 0.01 mg/kg (P<0.05). 
Effect of Tamsulosin on the iNOS Expression in the Bladder
The iNOS (130 kDa) protein expression in the bladder is pre-
sented in Fig. 4. The expression of the iNOS protein was 1.87± 
0.27 in the control group, 2.79±0.22 in the OAB-induced group, 
2.24±0.09 in the OAB-induced and 0.01 mg/kg tamsulosin-
treated group, 2.64±0.14 in the OAB-induced and 0.1 mg/kg 
tamsulosin-treated group, and 2.89±0.21 in the OAB-induced 
and 1 mg/kg tamsulosin-treated group. 
  These results showed that iNOS expression in the bladder 
was increased by induction of OAB (P<0.05) and that tamsu-
losin treatment significantly decreased OAB-induced NOS ex-
pressions in the bladder (P<0.05). The suppressing effect of 
tamsulosin on NOS expressions appeared at the 0.01 mg/kg 
dose (P<0.05). 
DISCUSSION
Cyclophosphamide is a chemotherapeutic drug that is effective 
in the treatment of various cancers. However, this drug induces 
severe chemical cystitis in animals and humans. It is well estab-
lished that this cystitis induces bladder overactivity, character-
ized by decreased bladder capacity and increased micturition 
frequency [20]. Thus, we used cyclophosphamide to induce 
OAB model in rats.
  Bladder filling and storage processes require accommodation 
to increasing urine volumes at low intravesical pressure with 
appropriate sensation, still sphincter remains closed during in-www.einj.org    19
  Kim, et al.  •  Effects of Tamsulosin on Overactive Bladder
http://dx.doi.org/10.5213/inj.2012.16.1.13
INJ
creasing in intra-abdominal pressure, and involuntary bladder 
contraction not appear [21]. For these reasons, normal detrusor 
function allows bladder filling during the storage phase, with 
little or no change in bladder pressure [1]. In contrast, OAB is 
the observation of involuntary detrusor contraction, and both 
increased bladder pressure and time [21]. The present study 
showed that contraction pressure and time were significantly 
increased after cyclophosphamide injection, indicating that cy-
Fig. 3. Effects of tamsulosin on nitric oxide synthase (NOS) expressions in the neuronal voiding centers (medial preoptic nucleus [MPA], 
ventrolateral periaqueductal gray [vlPAG], pontine micturition center [PMC], spinal cord [L4-L5] regions) after the induction of over-
active bladder (OAB). Upper: Photomicrographs of nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d)-positive 
cells in the neuronal voiding centers. The sections were stained for NOS like immunoreactivity (blue). The scale bar represents 200 μm. 
Control group (CON), OAB-induced group (OAB), OAB-induced and 0.01 mg/kg tamsulosin-treated group (OAB-T-0.01). Lower: 
Number of NADPH-d-positive cells in each group. (A) Control group, (B) OAB-induced group, (C) OAB-induced and 0.01 mg/kg 
tamsulosin-treated group, (D) OAB-induced and 0.1 mg/kg tamsulosin-treated group, (E) OAB-induced and 1 mg/kg tamsulosin-
treated group. 
a-d)Statistically significant differences (P<0.05) after Duncan post-hoc test. For example, groups marked with different 
letters differ statistically.
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clophosphamide deteriorated bladder function and as a result, 
induced OAB. 
  The PMC play an important role in the control of urinary 
bladder function. Activation of PMC neurons induces bladder 
contractions and relaxation of the bladder neck and external 
urethral sphincter, which results in micturition. Two regions 
associated with the PMC are PAG and MPA of the hypothala-
mus [5]. The PAG-PMC projection is considered to take part in 
the micturition reflex. The vlPAG acts as a central sensorimotor 
integrative relay of the micturition reflex, via the reception of 
sensory information concerning bladder fullness and the direct 
projection to the PMC [6]. In addition, the PMC is densely in-
nervated by the MPA [6]. The MPA sends projections to the 
PMC that synapse on neurons directly though projections to 
the spinal cord [5]. Bladder filling information from sensory 
interneurons in the lumbar spinal cord finally reaches to PMC 
in order to empty the bladder at appropriate time [22]. Electrical 
or chemical stimulation on the lower urinary tract was shown to 
cause changes in neuronal activity in the micturition centers, 
such as the PMC, PAG, MPA, and spinal cord [22,23]. Bon et 
al. [23] reported that injection of cyclophosphamide caused 
cystitis and increased number of c-Fos-positive cells in the PMC. 
Noxious stimulation of deep structures, such as muscle, joint, 
and viscera provoked a significant increase in the number of c-
Fos-positive neurons in the vlPAG [24]. Chung et al. [25] indi-
cated that chemical irritation on bladder provoked c-Fos ex-
pression in the PAG and MPA of the rats. Acute or chronic blad-
der irritation increased immediate early gene expression in the 
spinal neurons [7]. In the present results, expressions of c-Fos 
in the neuronal voiding centers (MPA, vlPAG, PMC, spinal cord 
[L4-L5] regions) were significantly increased after cyclophos-
phamide injection, indicating that induction of the OAB acti-
vated neurons in the voiding centers. 
  The exact mechanisms by which NO in the neuronal voiding 
centers modulates micturition are not fully understood. How-
ever, because NO regulates components of the lower urinary 
tract such as the bladder and urethra, NO levels in the neuronal 
voiding centers may also control the lower urinary tract status 
[26]. Gene expression and neurotransmitter synthesis in the 
brain can be altered by pain, peripheral irritation, and inflam-
mation [26]. In the present results, expressions of NOS in the 
neuronal voiding centers (MPA, vlPAG, PMC, spinal cord [L4-
L5] regions) were significantly increased after cyclophospha-
mide injection, indicating that induction of the OAB enhanced 
NO levels in the neuronal voiding centers. 
  As shown in this study, we suggest the relation of cyclophos-
phamide-induced expressions of c-Fos and NO in the neuronal 
voiding centers with cyclophosphamide-induced OAB symp-
toms. Enhanced expressions of c-Fos and NOS in the voiding 
centers activate neurons in the voiding centers and trigger OAB 
symptoms.
  Increasing of NO production by iNOS exerts detrimental ef-
fect on bladder, such as overactive bladder [11,27]. Up-regula-
tion of iNOS was detected after cyclophosphamide injection, li-
popolysaccharide instillation, and during urinary obstruction 
[28]. iNOS expression is closely implicated in the bladder in-
flammation and injury [11,13]. Inhibition of iNOS activity in 
OAB animal model significantly attenuated the increase of 
bladder size and bladder contraction number and suppressed 
bladder fibrosis [29]. In the present results, iNOS expression in 
the bladder was significantly increased after cyclophosphamide 
injection, indicating that cyclophosphamide induced inflam-
mation of bladder. 
  Change of α1-adrenoceptors expression in human blood ves-
sels, spinal cord, ganglia, and nerve terminals has been postu-
Fig. 4. Effects of tamsulosin on the expressions of inducible niric 
oxide synthase (iNOS) protein in the bladder after the induction 
of overactive bladder (OAB). Actin was used as an internal con-
trol (46 kDa). (A) Control group, (B) OAB-induced group, (C) 
OAB-induced and 0.01 mg/kg tamsulosin-treated group, (D) 
OAB-induced and 0.1 mg/kg tamsulosin-treated group, (E) 
OAB-induced and 1 mg/kg tamsulosin-treated group. 
a-b)Statis-
tically significant differences (P<0.05) after Duncan post-hoc 
test. For example, groups marked with different letters differ sta-
tistically.
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lated to contribute to the pathogenesis of lower urinary tract 
symptoms [30]. Activation of α1-adrenoceptors in bladder 
causes OAB symptoms, such as outflow obstruction, bladder 
instability, and frequent micturition [31]. Thus, the beneficial 
effect of α1-adrenergic receptor antagonists is a class effect in 
micturition function. Treatment with α1-adrenergic receptor 
antagonists relieves bladder obstruction, and may control void-
ing function by acting at bladder wall and spinal cord [32]. In 
human research, daytime frequency, nocturia, and incontinence 
episodes were significantly decreased with α1-adrenergic recep-
tor antagonists [33]. Moreover, α1-adrenergic receptor antago-
nists significantly increased bladder capacity and decreased fre-
quency [34]. In the present results, OAB-evoked increase of 
contraction pressure and time in the bladder was significantly 
suppressed by tamsulosin treatment. This suppressing effect of 
tamsulosin on contraction pressure and time can be ascribed to 
antagonizing effect of tamsulosin at α1-adrenergic receptors in 
the detrusor muscle or at prejunctional α1-adrenoceptors. This 
inhibition of tamsulosin may induce alteration of NO level in 
the lower urinary tract. The present study showed that iNOS 
protein expression in the bladder was significantly decreased by 
tamsulosin treatment. These results reveal that tamsulosin sup-
pressed bladder inflammation, and as a result, alleviated the cy-
clophosphamide-induced OAB symptoms. 
  During the storage phase, continence is maintained by inhi-
bition of the parasympathetic system and by activation of the 
sympathetic system, through the acting of α1-adrenergic recep-
tors, leads to compression of urethral sphincter and bladder. 
Conversely, during voiding, the PMC inhibits the sympathetic 
system and activates the parasympathetic system, resulting in a 
sustained relaxation of urethral sphincter and bladder [16]. In 
the present results, antagonizing effect of tamsulosin on α1-
adrenergic receptors suppressed the OAB-induced expressions 
of c-Fos and NOS in the neuronal voiding centers. The inhibi-
tory effects of tamsulosin on the expressions of c-Fos and NOS 
appeared most potently at the 0.01 mg/kg dose. These results 
show that tamsulosin may exert inhibitory effect on neuronal 
activation in the voiding centers and delay triggering of OAB 
symptoms. 
  From the present results, α1-adrenergic receptor antagonist 
tamsulosin may overcome OAB-induced micturition dysfunc-
tion through inhibition of neuronal voiding centers, thus we 
raise the possibility that tamsulosin is effective therapeutic mo-
dality for ameliorating the symptoms of OAB.
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